Mr. Yusheng Han is our Founder, Chairman of the Board of Directors and Chief  Executive Officer. Mr. Han has nearly two decades of experience in the life science industry. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as the General Manager in China. During his term tenure with BioTek Instruments China, he built and led teams across Marketing, Sales and Post-Sale. From September 2003 to May 2005, he served as a Product Specialist at Gene Company Limited. Mr. Han received a Bachelor's degree in Biochemistry from Jilin University in July 2000, and a Master's degree in Cell Biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.

Xinru Mao is head of pharma services and head of international IVD business of Burning Rock. She is responsible for leading the pharma biomarker and CDx services including business development, translation medicine and project operations globally. She also leads the IVD international business including go-to-market strategy, commercialization of arrays, and channel partner development and support within the regions for Americas, Europe, Japan, Middle East, etc.

Dr. Xinru Mao has over 16-year experiences of innovative drug clinical development and NGS-driven precision medicine in oncology therapy. Dr Mao has been with BNR since 2015 and has held several positions with the company. During the five years prior current roles, she served as medical director who leaded the medical affairs team.

Prior to BNR, she worked in AstraZeneca R&D department, and leaded several important new compounds clinical development in oncology and CNS areas.